Displaying 13 - 24 of 33
Viral Hepatitis
5

Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
6

Gilead Sciences: A new beginning in hepatitis delta - ILC 2021

View
Viral Hepatitis
5

Gilead Sciences: The Next Chapter in Viral Hepatitis - ILC 2021

View
Viral Hepatitis
5

Gilead Sciences: The Next Chapter in Viral Hepatitis - ILC 2021

View
Displaying 13 - 24 of 33